Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC

24-02-2017

Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC

RiverNorthPhotography / iStockphoto.com

The Federal Trade Commission (FTC) has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.


FTC, Abbott, M&A, anticompetitive, St. Jude Medical, Terumo Corporation

More on this story

FTC hails M&A activity in ‘historic’ 2016
29-03-2017

LSIPR